The Single Best Strategy To Use For iMDK
All enrolled people who obtained a minimum of just one dose of zosuquidar or placebo for the duration of induction were being monitored for your event of adverse gatherings (439 people, 219 on zosuquidar and 210 on placebo). The commonest adverse events have been connected to the duration of extended and major myelosuppression as is expected with i